Código QR

Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A

Abstract: Acquired hemophilia A (AHA) is a severe bleeding disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII). Standard treatment involves immunosuppressive therapy (IST), which carries a significant risk of serious infections, the leading cause of death in patien...

Descripción completa

Guardado en:
Autores principales: Inga M. Schimansky, Christiane Dobbelstein, Robert Klamroth, Christina Hart, Ulrich J. Sachs, Richard Greil, Paul Knöbl, Johannes Oldenburg, Wolfgang Miesbach, Christian Pfrepper, Karolin Trautmann-Grill, Patrick Möhnle, Katharina Holstein, Hermann Eichler, Sonja Werwitzke, Andreas Tiede
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier 2025-11-01
Colección:Blood Advances
Acceso en línea:http://www.sciencedirect.com/science/article/pii/S2473952925004847
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares